1,7-DimethoxyxanthoneCAS# 5042-06-8 |
Quality Control & MSDS
Package In Stock
Number of papers citing our products
| Cas No. | 5042-06-8 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C15H12O4 | M.Wt | 256.3 |
| Type of Compound | Xanthones | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
1,7-Dimethoxyxanthone Dilution Calculator
1,7-Dimethoxyxanthone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9017 mL | 19.5084 mL | 39.0168 mL | 78.0336 mL | 97.5419 mL |
| 5 mM | 0.7803 mL | 3.9017 mL | 7.8034 mL | 15.6067 mL | 19.5084 mL |
| 10 mM | 0.3902 mL | 1.9508 mL | 3.9017 mL | 7.8034 mL | 9.7542 mL |
| 50 mM | 0.078 mL | 0.3902 mL | 0.7803 mL | 1.5607 mL | 1.9508 mL |
| 100 mM | 0.039 mL | 0.1951 mL | 0.3902 mL | 0.7803 mL | 0.9754 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Swertianin 2-O-α-L-rhamnopyranosyl-(1→2)-β-D-xylopyranoside
Catalog No.:BCN0622
CAS No.:136832-00-3
- Bisisorhapontigenin C
Catalog No.:BCN0621
CAS No.:
- cis-Methylisoeugenol
Catalog No.:BCN0620
CAS No.:6380-24-1
- threo-1-(4-Hydroxyphenyl)propane-1,2,3-triol
Catalog No.:BCN0619
CAS No.:155748-73-5
- 6″-O-Acetylsaikosaponin b3
Catalog No.:BCN0618
CAS No.:104109-34-4
- 16-Oxolyclanitin-29-yl p-coumarate
Catalog No.:BCN0617
CAS No.:140701-70-8
- Thalmineline
Catalog No.:BCN0616
CAS No.:28328-00-9
- 2-Ethyl-3-methylmaleimide N-β-D-glucopyranoside
Catalog No.:BCN0615
CAS No.:182228-46-2
- Aristolactam IIIa N-β-glucoside
Catalog No.:BCN0614
CAS No.:80311-26-8
- 1,1'-[1,4-Phenylenebis(methylene)]bis[4,8,11-tris[(4-methylphenyl)sulfonyl]-1,4,8,11-tetraazacyclotetradecane
Catalog No.:BCN0613
CAS No.:110078-47-2
- (S)-(-)-2-Amino-3-methyl-1,1-diphenyl-1-butanol
Catalog No.:BCN0612
CAS No.:78606-95-9
- 1,6,2',3',6'-O-Pentaacetyl-3-O-trans-p-coumaroylsucrose
Catalog No.:BCN0611
CAS No.:138213-63-5
- (+)-Perillaldehyde
Catalog No.:BCN0624
CAS No.:5503-12-8
- 8,9-Dehydrothymol isobutyrate
Catalog No.:BCN0625
CAS No.:38146-79-1
- 3-Hydroxy-p-menth-1-en-6-one
Catalog No.:BCN0626
CAS No.:61570-82-9
- 1,6,2',6'-O-Tetraacetyl-3-O-trans-p-coumaroylsucrose
Catalog No.:BCN0627
CAS No.:138195-49-0
- Ethyl 3,5-di-O-caffeoylquinate
Catalog No.:BCN0628
CAS No.:143051-74-5
- Ethyl 13-hydroxy-α-linolenate
Catalog No.:BCN0629
CAS No.:123435-84-7
- Campsiketalin
Catalog No.:BCN0630
CAS No.:93675-96-8
- Colelomycerone A
Catalog No.:BCN0631
CAS No.:1191896-73-7
- Annphenone
Catalog No.:BCN0632
CAS No.:61775-18-6
- (3S,5S)-[4]-Gingerdiol
Catalog No.:BCN0633
CAS No.:1448789-37-4
- Calophyllic acid
Catalog No.:BCN0634
CAS No.:36626-19-4
- Isocalophyllic acid
Catalog No.:BCN0635
CAS No.:157810-76-9
Network pharmacology study on the mechanism of Qiangzhifang in the treatment of panic disorder.[Pubmed:34532487]
Ann Transl Med. 2021 Aug;9(16):1350.
Background: Panic disorder (PD) is a kind of mental illness characterized by the symptom of recurring panic attacks. Qiangzhifang (QZF) is a novel decoction developed by Professor Zhaojun Yan based on a unique system of syndrome differentiation and clinical experience. It has achieved remarkable results after long-term clinical practice, but its mechanism of action is still unclear. This study aims to use network pharmacology and molecular docking to explore the mechanism of QZF in the treatment of PD. Methods: We used the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), a literature search, and Encyclopedia of Traditional Chinese Medicine (ETCM) to find active ingredients and targets of QZF. We searched for PD targets in GeneCards, Online Mendelian Inheritance in Man (OMIM), the Comparative Toxicogenomics Database (CTD), and DrugBank. We established a PD target database, constructed a protein-protein interaction (PPI) network, and performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis in order to screen possible pathways of action and analyze the mechanism. Results: This study identified 84 effective components of QZF, 691 potential targets, 357 PD targets, and 97 intersectional targets. Enrichment analysis using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) showed that QZF was associated with 118 biological processes (BPs), 18 cellular components (CCs), 35 molecular functions (MFs) [false discovery rate (FDR) <0.01], and 62 pathways (FDR <0.01). QZF mainly acts on its targets AKT1, FOS, and APP through active ingredients such as quercetin, beta-sitosterol, 4-(4'-hydroxybenzyloxy)benzyl methyl ether, harmine, 1,7-Dimethoxyxanthone, and 1-hydroxy-3,7-dimethoxyxanthone to regulate serotonin, gamma-aminobutyric acid (GABA), cyclic adenosine monophosphate (cAMP), and other signal pathways to treat PD. Conclusions: Through network pharmacology and molecular docking technology, we predicted the possible mechanism of QZF in the treatment of PD, revealed the interaction targets and potential value of QZF, and provided a basis for its clinical application.
